{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:51:47Z","timestamp":1782305507768,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KFO 303"],"award-info":[{"award-number":["KFO 303"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40257-020-00563-7","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T08:04:57Z","timestamp":1602057897000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"22","author":[{"given":"Sascha","family":"St\u00e4nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9151","authenticated-orcid":false,"given":"Khalaf","family":"Kridin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"issue":"1","key":"563_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","volume":"66","author":"K Kridin","year":"2018","unstructured":"Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6\u201317. https:\/\/doi.org\/10.1007\/s12026-017-8975-2.","journal-title":"Immunol Res"},{"key":"563_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","volume":"5","author":"K Kridin","year":"2018","unstructured":"Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med. 2018;5:220. https:\/\/doi.org\/10.3389\/fmed.2018.00220.","journal-title":"Front Med."},{"issue":"6","key":"563_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","volume":"78","author":"M Benzaquen","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard M-A, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78(6):1090\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.038.","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"563_CR4","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","volume":"138","author":"O Varpuluoma","year":"2018","unstructured":"Varpuluoma O, F\u00f6rsti A-K, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol. 2018;138(7):1659\u201361. https:\/\/doi.org\/10.1016\/j.jid.2018.01.027.","journal-title":"J Invest Dermatol."},{"issue":"5","key":"563_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","volume":"233","author":"C Schaffer","year":"2017","unstructured":"Schaffer C, Buclin T, Jornayvaz FR, Cazzaniga S, Borradori L, Gilliet M, et al. Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid. Dermatology. 2017;233(5):401\u20133. https:\/\/doi.org\/10.1159\/000480498.","journal-title":"Dermatology"},{"issue":"10","key":"563_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","volume":"154","author":"K Kridin","year":"2018","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes. JAMA Dermatol. 2018;154(10):1152\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2352.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"563_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","volume":"42","author":"A Douros","year":"2019","unstructured":"Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. Diabetes Care. 2019;42(8):1496\u2013503. https:\/\/doi.org\/10.2337\/dc19-0409.","journal-title":"Diabetes Care"},{"issue":"2","key":"563_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","volume":"155","author":"SG Lee","year":"2019","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155(2):172\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4556.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"563_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","volume":"139","author":"M Plaquevent","year":"2019","unstructured":"Plaquevent M, T\u00e9tart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P, et al. Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the french general population. J Invest Dermatol. 2019;139(4):835\u201341. https:\/\/doi.org\/10.1016\/j.jid.2018.10.045.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"563_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556;","volume":"155","author":"H Lee","year":"2019","unstructured":"Lee H, Chung HJ, Pawar A, Patorno E, Kim DH. Evaluation of risk of bullous pemphigoid with initiation of dipeptidyl peptidase-4 inhibitor vs second-generation sulfonylurea. JAMA Dermatol. 2019;155(2):172\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4556;.","journal-title":"JAMA Dermatol"},{"key":"563_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.048","author":"K Kridin","year":"2018","unstructured":"Kridin K, Cohen AD. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol. 2018. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.048.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"563_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jid.2018.11.025","volume":"139","author":"W Nishie","year":"2019","unstructured":"Nishie W, Tasanen K. Gliptin-associated bullous pemphigoid: a valuable model of the mechanism of breakdown of immune tolerance against BP180. J Invest Dermatol. 2019;139(4):755\u20136. https:\/\/doi.org\/10.1016\/j.jid.2018.11.025.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"563_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/25785826.2019.1619233","volume":"42","author":"W Nishie","year":"2019","unstructured":"Nishie W. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics. Immunol Med. 2019;42(1):22\u20138. https:\/\/doi.org\/10.1080\/25785826.2019.1619233.","journal-title":"Immunol Med"},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","volume":"10","author":"K Tasanen","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019;10:1238. https:\/\/doi.org\/10.3389\/fimmu.2019.01238.","journal-title":"Front Immunol."},{"issue":"5","key":"563_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/1346-8138.14245","volume":"45","author":"C Chijiwa","year":"2018","unstructured":"Chijiwa C, Takeoka S, Kamata M, Tateishi M, Fukaya S, Hayashi K, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. J Dermatol. 2018;45(5):596\u20139. https:\/\/doi.org\/10.1111\/1346-8138.14245.","journal-title":"J Dermatol."},{"issue":"11","key":"563_CR16","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","volume":"136","author":"K Izumi","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016;136(11):2201\u201310. https:\/\/doi.org\/10.1016\/j.jid.2016.06.622.","journal-title":"J Invest Dermatol."},{"issue":"6","key":"563_CR17","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bjd.16479","volume":"178","author":"H Horikawa","year":"2018","unstructured":"Horikawa H, Kurihara Y, Funakoshi T, Umegaki-Arao N, Takahashi H, Kubo A, et al. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol. 2018;178(6):1462\u20133. https:\/\/doi.org\/10.1111\/bjd.16479.","journal-title":"Br J Dermatol"},{"issue":"5","key":"563_CR18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","volume":"138","author":"H Ujiie","year":"2018","unstructured":"Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018;138(5):1201\u20134. https:\/\/doi.org\/10.1016\/j.jid.2017.11.023.","journal-title":"J Invest Dermatol."},{"issue":"6","key":"563_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2340\/00015555-3166","volume":"99","author":"O Lindgren","year":"2019","unstructured":"Lindgren O, Varpuluoma O, Tuusa J, Ilonen J, Huilaja L, Kokkonen N, et al. Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid. Acta Derm Venereol. 2019;99(6):602\u20139. https:\/\/doi.org\/10.2340\/00015555-3166.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"563_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1684\/ejd.2018.3371","volume":"28","author":"A Patsatsi","year":"2018","unstructured":"Patsatsi A, Kyriakou A, Meltzanidou P, Trigoni A, Lamprou F, Kokolios M, et al. Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid? Eur J Dermatol. 2018;28(5):711\u20133. https:\/\/doi.org\/10.1684\/ejd.2018.3371.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"563_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","volume":"78","author":"L Fania","year":"2018","unstructured":"Fania L, Salemme A, Provini A, Pagnanelli G, Collina MC, Abeni D, et al. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. J Am Acad Dermatol. 2018;78(3):592\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"563_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ddg.14097_g","volume":"18","author":"E Schmidt","year":"2020","unstructured":"Schmidt E, Goebeler M, Hertl M, Sardy M, Sitaru C, Eming R, et al. S2k-Leitlinie zur Diagnostik des Pemphigus vulgaris\/foliaceus und des bull\u00f6sen Pemphigoids. JDDG J German Soc Dermatol. 2020;18(5):516\u201327. https:\/\/doi.org\/10.1111\/ddg.14097_g.","journal-title":"JDDG J German Soc Dermatol"},{"issue":"3","key":"563_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.032.","journal-title":"J Am Acad Dermatol"},{"key":"563_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J B\u00e9n\u00e9","year":"2016","unstructured":"B\u00e9n\u00e9 J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case\u2013noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175:296\u2013301.","journal-title":"Br J Dermatol"},{"issue":"2","key":"563_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","volume":"155","author":"K Kridin","year":"2019","unstructured":"Kridin K, Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid. JAMA Dermatol. 2019;155(2):166\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5049.","journal-title":"JAMA Dermatol"},{"key":"563_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13790","author":"K Kridin","year":"2020","unstructured":"Kridin K. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/dth.13790.","journal-title":"Dermatol Ther."},{"key":"563_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3389\/fimmu.2019.01439","volume":"10","author":"K Izumi","year":"2019","unstructured":"Izumi K, Nishie W, Beniko M, Shimizu H. A cross-sectional study comparing the prevalence of bullous pemphigoid autoantibodies in 275 cases of type II diabetes mellitus treated with or without dipeptidyl peptidase-IV inhibitors. Front Immunol. 2019;10:1439. https:\/\/doi.org\/10.3389\/fimmu.2019.01439.","journal-title":"Front Immunol."},{"key":"563_CR28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3389\/fimmu.2019.01224","volume":"10","author":"Y Mai","year":"2019","unstructured":"Mai Y, Nishie W, Izumi K, Shimizu H. Preferential reactivity of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180. Front Immunol. 2019;10:1224. https:\/\/doi.org\/10.3389\/fimmu.2019.01224.","journal-title":"Front Immunol."},{"issue":"8","key":"563_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/exd.12171","volume":"22","author":"M Collin","year":"2013","unstructured":"Collin M, Ehlers M. The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol. 2013;22(8):511\u20134. https:\/\/doi.org\/10.1111\/exd.12171.","journal-title":"Exp Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00563-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00563-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00563-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T23:29:47Z","timestamp":1633562987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00563-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00563-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"7 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided by Projekt DEAL. Clinical Research Unit Pemphigoid Diseases (KFO 303) and Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) are both funded by Deutsche Forschungsgemeinschaft.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sascha St\u00e4nder, Enno Schmidt, Detlef Zillikens, Ralf J. Ludwig, and Khalaf Kridin have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study was approved by the appropriate institutional research ethics committee of the University of L\u0171beck (20-110A). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Raw data are available on request from the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KK and SS had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: KK and RJL. Acquisition, analysis, and interpretation of data: KK and RJL. Drafting of the manuscript: KK. Critical revision of the manuscript for important intellectual content: ES and DZ. Statistical analysis: KK. Study supervision: SS. All authors have read and approved the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}